


BMJ Open Specialised orthotic care to improve functioning in adults with neuromuscular disorders: protocol of a prospective randomised open-label blinded end-point study

Elza van Duijnhoven ¹, Fieke Sophia Koopman,¹
Jana Antonius Maria Tuijelaars,¹ Viola Altmann,² Rimke Lagrand,¹
Johanna Maria van Dongen,³ Frans Nollet,¹ Merel-Anne Brehm¹

To cite: van Duijnhoven E, Koopman FS, Tuijelaars JAM, *et al*. Specialised orthotic care to improve functioning in adults with neuromuscular disorders: protocol of a prospective randomised open-label blinded end-point study. *BMJ Open* 2020;**10**:e039683. doi:10.1136/bmjopen-2020-039683

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-039683>).

Received 22 April 2020
Revised 19 October 2020
Accepted 21 October 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

¹Department of Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

²Klimmendaal Rehabilitation Center, Arnhem, The Netherlands

³Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Correspondence to
Elza van Duijnhoven;
e.vanduijnhoven@amsterdamumc.nl

ABSTRACT

Introduction People suffering from leg muscle weakness caused by neuromuscular disorders (NMDs) are often provided with leg orthoses to reduce walking problems such as increased walking effort, diminished walking speed, reduced balance and falls. However, evidence for the effectiveness of leg orthoses to improve walking in this patient group is limited and there is an absence of standardised practice in orthotic prescription. In 2012 a Dutch multidisciplinary guideline was developed aimed to standardise the orthotic treatment process in NMD. Although application of the guideline in expert centres (specialised orthotic care) seems beneficial regarding clinical effectiveness, larger studies are necessary to confirm results and investigate cost-effectiveness. Therefore, this study aims to examine the effectiveness and cost-effectiveness of specialised orthotic care compared with usual orthotic care in adults with slowly progressive NMD.

Methods and analysis A prospective randomised open-label blinded end-point study will be performed, in which 70 adults with slowly progressive NMD are randomly assigned to specialised orthotic care (intervention) or usual orthotic care (control). Outcome measures are assessed at baseline and at 3 and 6 months follow-up. The primary endpoints are gross walking energy cost (J/kg/m) assessed during a 6 min walk test and achievement of personal goals, measured with the Goal Attainment Scale. Secondary endpoints include walking speed, gait biomechanics, stability, physical functioning, falls and fear of falling, perceived fatigue and satisfaction. For the economic evaluation, societal costs and health-related quality of life will be assessed using cost questionnaires and the 5-Level version of EuroQol 5 Dimension, retrospectively.

Ethics and dissemination The study is registered in the Dutch trial register (NL 7511) and the protocol has been approved by the Medical Ethics Committee of the Academic Medical Center in Amsterdam. Results will be presented at national and international scientific conferences and disseminated through peer-reviewed journals and media aimed at a broad audience including patients.

Strengths and limitations of this study

- A broad range of outcome measures, both objective and self-reported, will be collected, resulting in a unique dataset of both functional effects, underlying biomechanical working mechanisms and costs.
- The two primary outcome measures to evaluate functional effects include walking energy cost and achievement of personal goals measured with the Goal Attainment Scale, which is chosen as an additional primary outcome measure to capture the diversity of orthotic goals relevant to the individual.
- Evidence will be obtained in a large group of adults with different slowly progressive neuromuscular disorders, which increases the generalisability of results.
- An economic evaluation will be performed alongside the study to provide insights into the cost-effectiveness of specialised orthotic care versus usual orthotic care.
- To account for the expected variability in treatment components of usual orthotic care, which is a possible limitation that could complicate the identification of underlying mechanisms of action between treatments, the process of usual orthotic care will be extensively documented.

INTRODUCTION

People with slowly progressive neuromuscular disorders (NMDs), such as postpolio syndrome and Charcot Marie Tooth disease, frequently suffer from leg muscle weakness.¹ Leg muscle weakness will change the gait pattern,² causing walking problems such as increased walking effort,^{3 4} diminished walking speed,^{3 4} pain,⁵ balance problems and falls.^{6 7} These walking problems may restrict the patients' performance of daily physical activities⁸ and negatively affect their independence and quality of life.^{8 9} Due to the



progressive nature of NMD, walking problems will gradually increase over time,⁹ which will further negatively affect physical mobility, independency and quality of life.

Leg orthoses are provided to reduce walking problems in people with NMD.¹⁰ A leg orthosis is an 'externally applied medical device encompassing (part of) the leg and foot, used to modify the structural and functional characteristics of the neuromuscular and skeletal systems'.¹¹ In general, an ankle-foot orthosis (AFO) is provided in case of distal leg muscle weakness, which often includes weakness of the foot dorsiflexors and plantarflexors.^{10 12} Accordingly, the AFO should support foot clearance during swing by restricting plantarflexion and compensate for plantarflexor weakness by restricting dorsiflexion during late stance.¹⁰ Knee-ankle-foot orthoses (KAFOs) are provided for (additional) proximal leg muscle weakness, particularly weakness of the quadriceps, to stabilise the knee joint during the stance phase of gait and allow safe weight-bearing.^{10 13}

In previous research, various types of AFOs for calf muscle weakness¹⁴ and KAFOs for quadriceps weakness have been found to improve walking in people with NMD.¹⁵ However, the strength of the evidence is rather limited due to a lack of proper study designs, relatively small sample sizes, and heterogeneity in types of leg orthoses and control conditions studied. Accordingly, there is a lack of evidence-based and standardised guidance on the application of leg orthoses. Furthermore, many different types of leg orthoses are being prescribed in current orthotic practice in NMD, varying largely in orthotic properties and effectiveness, with both good and suboptimal treatment outcomes in terms of improving walking.^{16 17}

In 2012, a Dutch multidisciplinary guideline for leg orthoses in adults with slowly progressive NMD was developed with the aim to standardise the treatment process and improve treatment outcomes.¹⁸ The guideline was developed according to proposed national and international frameworks¹⁹⁻²¹ and compromises the entire process of orthotic treatment in systematically divided steps, as well as treatment algorithms for the selection of leg orthoses. According to the guideline, the care need should be individually characterised in terms of the personal health problems, goals and gait deviations to be addressed, caused by the underlying impairments. Based on the care need, the orthotic goals should be defined and matched with the orthosis design. Gait training after delivery of the orthosis after is essential to maximise effectiveness.²² Finally, it is important to systematically evaluate the effectiveness as well as user experiences to ensure the functionality of the orthosis.²³

At this moment, the guideline is not widely applied throughout the Netherlands, as it requires sufficient expertise of the multidisciplinary care team involved and facilities for advanced 3-dimensional (3D)-gait analysis and gait training. However, prescribing leg orthoses according to the guideline (i.e. specialised orthotic care) seems promising in terms of clinical effectiveness

as recently shown in two uncontrolled trials.^{16 24} In individuals with calf muscle weakness due to NMD, individually stiffness-optimised AFOs have been shown to reduce walking effort to a much greater extent compared with AFOs prescribed in usual orthotic care.²⁴ Furthermore, in polio survivors,¹⁶ the increment in walking effort with KAFOs prescribed in specialised orthotic care was reduced with 18% towards normative values, when compared with usual care KAFOs. At this moment, the effectiveness of leg orthoses prescribed within specialised orthotic care on functioning needs to be investigated in a larger group of individuals with slowly progressive NMD in comparison to usual orthotic care to strengthen evidence for the possible benefit.

While good-quality studies are needed to strengthen the evidence for the effectiveness of specialised orthotic care in NMD, it is also imperative to investigate whether the treatment is cost-effective, which is currently unknown. Since new and expensive orthotic devices increasingly become available, it is important to assess their associated costs.²⁵ Also, at this moment, an important problem in usual orthotic care concerns the low compliance of patients wearing their devices,²⁶ which in turn leads to an inefficient use of healthcare resources.²⁷ Optimally matching orthoses with the personal needs and goals of the patient, according to the guideline, could lead to gains in clinical effectiveness and subsequently a higher compliance. In this respect, specialised orthotic care could improve the efficiency of (healthcare) resource, but this has not yet been investigated.

The aim of this study is to examine the effectiveness and cost-effectiveness of specialised orthotic care compared with usual orthotic care on functioning in adults with NMD. We hypothesise that specialised orthotic care is more effective in terms of reducing walking effort and achieving personal goals when compared with usual orthotic care. Furthermore, specialised orthotic care is expected to be cost-effective compared with usual orthotic care from a societal and healthcare perspective.

METHODS AND ANALYSIS

Study design

The study is designed as a randomised open-label blinded end-point study that is prospectively registered at the Dutch Trial Register under number NL7511. The trial protocol was developed according to the Standard Protocol Items: Recommendations for Interventional Trials guidelines²⁸ (online supplemental file 1). Recruitment started in March 2019 and is foreseen to end at December 2021. Measurements are conducted at baseline (T1) and 3 and 6 months after orthotic treatment is given (T2 and T3, respectively). To determine the cost-effectiveness, an economic evaluation is performed alongside the study. An overview of the study design is shown in [figure 1](#).




Figure 1 Overview of the study design.

Study population

We intend to include 70 adults with slowly progressive NMD (such as Charcot-Marie-Tooth disease, post-polio syndrome, inclusion body myositis or myotonic dystrophy) or peripheral nerve injury who have non-spastic leg muscle weakness. For eligibility, patients may or may not use an orthosis provided in usual care at the time of recruitment. Patients will be recruited from rehabilitation centres and hospitals throughout the Netherlands and through the Dutch Association for Neuromuscular Diseases. If a patient is willing to participate, a screening visit is planned. During the screening visit, written informed consent (online supplemental file 2) is obtained and the investigator, in close collaboration with a rehabilitation physician, will check the inclusion and exclusion criteria.

Inclusion criteria are: (1) minimum age of 18 years, (2) weakness of the calf muscles (ie, Medical Research Council (MRC) scale²⁹ score <5 or not being able to make a heel-rise on one leg >3 times) and/or weakness of the quadriceps (ie, MRC score <5) (3) experiencing walking problems such as increased walking effort, pain and/or impaired balance during standing and/or walking, (4) able to walk for 6 min at comfortable speed with or without assistive device (eg, cane, crutch, walker), (5) indicated for an orthosis based on physical examination and 3D gait analysis and (6) motivated to use an orthosis. An exclusion criterion is: (1) insufficient mastery of the Dutch language.

Sample size

The sample size of this study is based on a power analysis of the expected differences in walking effort (defined as gross walking energy cost) and the achievement of personal treatment goals between the intervention and control group. According to previous studies,^{16 17} a difference in change in walking energy cost of 0.60 J/kg/m from baseline to 6 months post-treatment is expected between usual orthotic care and specialised orthotic care, where a difference of at least 0.45 J/kg/m is considered as clinically relevant.³ Based on an intention-to-treat analysis, alpha of 0.05, power of 80% and using an estimated correlation coefficient of the repeated measures of 0.76 and SD of 0.90 J/kg/m, 30 patients per treatment group are necessary. The goal is to include 70 patients allowing for a 15% drop-out. This sample size also allows the detection of 1 point difference in personal achievement goal scores (Based on an intention-to-treat analysis, alpha of 0.05, power of 80%, and using an estimated correlation coefficient of the repeated measures of 0.70).

Randomisation and blinding

After baseline measurement (T1), participants will be randomly assigned in a 1:1 ratio to receive specialised orthotic care (intervention group) or usual orthotic care (control group). The randomisation scheme will be computer generated in Castor (Castor EDC, Amsterdam, the Netherlands) and uses blocks of random sequences with variable sizes (2, 4 and 6). Patients will be stratified by

disease severity defined as distal leg weakness versus (distal and) proximal leg weakness, respectively. Outcomes will be assessed by a blinded and independent assessor. When patients are informed of group allocation, they will be instructed not to reveal this to the outcome assessor.

Intervention

Specialised orthotic care

Patients in the intervention group will receive specialised orthotic care at an expert centre that has implemented the Dutch guideline for leg orthoses¹⁸ and has facilities for 3D gait analysis, gait training and fabricating custom-made leg orthoses. For the orthotic care process, protocols of the guideline will be used and treatment integrity checks will be performed to ensure compliance with the guideline.

First, the health problems and goals of the patient will be assessed by means of an interview, questionnaires, physical examination and 3D gait analysis. Based on these assessments, the multidisciplinary care team will identify how the patients' problems and goals are best matched to an orthotic solution. The desired level of functioning for the patient and the required orthotic functions will be described in a care plan. Accordingly, the orthosis will be custom fabricated by an orthotic technician. After delivery of the orthosis, instructions on use and maintenance will be given to the patient and, when indicated, the patient receives gait training supervised by an experienced physiotherapist. Finally, after 3 months of using the orthosis, experiences of the patient as well as the desired level of functioning and orthotic functions will be evaluated. When needed, the orthosis will be adjusted based on the evaluation. The provision process will be extensively documented for each participant individually by an investigator who is not blinded.

Usual orthotic care

Participants in the control group will receive usual orthotic care from a rehabilitation physician at their regular care centre. Treatment can vary across centres and may include provision of orthopaedic shoes, provision of off-the-shelf or custom-made AFOs or provision of off-the-shelf or custom-made KAFOs according to the discretion of the practitioners and local policy of the centre. For participants who already use an orthosis at baseline, usual orthotic care will concern the provision of a new orthosis which may be identical or different from the orthosis being used. The provision process in the usual care centres will be extensively documented for each participant individually by an investigator who is not blinded.

Outcome measures

Relevant demographic variables, anthropometrics and clinical characteristics will be measured at baseline (T1). Clinical characteristics to be evaluated include: (1) manually assessed muscle strength of the left and right hip flexors and extensors, hip abductors and adductors, knee

flexors and extensors, ankle plantar and dorsal flexors and ankle invertors and evertors, scored according to the MRC scale and (2) passive range of motion of the hip, knee and ankle joints (left and right). Furthermore, (3) occurrence of joint deformities and (4) impairments in sensory function will be evaluated.

Primary outcomes and secondary outcomes (described below) will be assessed at baseline (T1) and at 3 and 6 months after orthotic treatment (T2 and T3, respectively). Additionally, orthotic properties (such as type, weight, material and orthotic functions) and adverse events due to the use of the device (such as pressure sores, pain, muscle soreness) will be documented. The use of any medication during the study will be monitored at all measurement time points and documented in the cost questionnaires. All collected outcomes will be entered into a Castor database. An overview of all outcomes per measurement visit is given in [table 1](#).

Primary outcomes

Primary outcomes are walking energy cost and the achievement of personal treatment goals. Walking energy cost will be determined during a 6-minute walk test (6MWT) in which participants walk at a self-selected comfortable speed on an indoor oval track in their preferred walking direction (which will be kept similar over measurement time points). Simultaneously, oxygen uptake (VO_2) and the respiratory exchange ratio (RER) will be measured breath by breath with the Cosmed K5 portable gas analysis system (Cosmed, Rome, Italy). Mean VO_2 , RER and walking speed values will be obtained at steady state from the last 3 min of the 6MWT using a custom-written Matlab script (V.2019; MathWorks, Natick, Massachusetts, USA). From these outcomes, walking energy cost in J/kg/m will be calculated by using the following formula: $((4.940 \times \text{RER}) + 16.040) \times \text{VO}_2 / \text{walking speed}$ where VO_2 is in mL/kg/min.³⁰ The assessment of walking energy cost has previously been shown to be reliable in patients with NMD.^{31 32}

The achievement of personal treatment goals will be quantified with the Goal Attainment Scale (GAS) to capture the diversity of orthotic treatment goals important to the individual patient.³³ At baseline, two goals that are highly relevant to the individual will be determined with the patient based on what they wish to achieve in daily life in terms of activities and participation according to the International Classification of Functioning, Disability and Health (ICF) framework.²⁰ Subsequently, personal GAS scales will be determined by creating six distinct levels of outcome ranging from -3 to +2, where the desired attainment goal of the patient is defined as 0 and the current situation is defined as -2. Achievement of the goals will be scored at T2 and T3 as -3=worsened, -2=unchanged, -1=somewhat less than expected, 0=expected outcome, +1 = somewhat more than expected and +2 = much more than expected. Improvements of at least two points will be regarded as

Table 1 Overview of outcomes per measurement session

		Baseline	Follow-up	
		T1 measurement (screening)	T2 measurement (12 weeks after delivery)	T3 measurement (24 weeks after delivery)
Primary outcomes				
Walking energy cost	6 MWT	X	X	X
Personal goals	GAS	<i>Setting goals</i>	X	X
Secondary outcomes				
Walking speed	6 MWT	X	X	X
Gait biomechanics	3DGA	X*	X	X
Stability	NRS	X	X	X
Physical functioning	SF36-PF	X	X	X
Fear of falling	FES	X	X	X
Fall rate	Questionnaire	X	X	X
Fatigue	FSS	X	X	X
Satisfaction	D-Quest	X†	X	X
Additional outcomes				
Demographics	Intake	X		
Anthropometrics	Physical exam	X		
Muscle strength	Physical exam	X		
Joint passive range of motion	Physical exam	X		
Sensory function	Physical exam	X		
Orthotic properties	CRF	X†	X	X
Adverse events	CRF		X	X
Economic evaluation				
Resource use‡	Cost questionnaire	X	X	X
Health-related quality of life‡	EQ-5D-5L	X	X	X

*Gait analysis conditions at baseline that will be used for statistical analysis concern walking with shoes only or walking with the old orthosis (in case a participant uses an orthosis at baseline).

†Outcomes will only be assessed in case a participant uses an orthosis at baseline.

‡Outcomes for the economic evaluation will also be assessed directly after delivery of the orthosis.

CRF, clinical report form; 3DGA, 3-dimensional gait analysis; D-Quest, Dutch version of the Quebec User Evaluation of Satisfaction with Assistive Technology; EQ-5D-5L, 5-Level version of EuroQol 5D; FES, Falls Efficacy Scale; FSS, Fatigue Severity Scale; GAS, Goal Attainment Scale; 6MWT, 6-minute walk test; NRS, Numeric Rating Scale; SF36-PF, Physical Functioning Scale of the Short-Form Health Survey.

clinical relevant.³⁴ The investigator defining and scoring the GAS, followed a course in applying GAS within a rehabilitation context.³⁵

Secondary outcomes

Secondary outcomes include walking speed (measured during the 6MWT), gait biomechanics (explained below), perceived stability during walking (assessed with a 11-point Numeric Rating Scale (NRS)), perceived physical functioning (PF) (assessed with the Short-Form Health Survey PF scale (SF36-PF)),³⁶ frequency of falls and fear of falling (assessed with the short version of the Falls Efficacy Scale (FES)),³⁷ perceived fatigue (assessed with the Fatigue Severity Scale (FSS))³⁸ and satisfaction with the orthosis (assessed with the Dutch version of the Quebec User Evaluation of Satisfaction with Assistive Technology (D-QUEST))³⁹ added with self-designed items).

Gait biomechanics

Gait biomechanics will be assessed with a 100 Hz 12-camera 3D motion capture system (VICON MX V.1.3) and two adjacent 1000 Hz force plates (OR6-7; AMTI, Watertown, Massachusetts, USA). Preparations include placement of reflective markers on the body according to the Plug-In Gait model. After a static calibration, participants will be asked to walk along a 12 m long walkway. Conditions that will be assessed include barefoot walking (T1), walking with the current orthosis if applicable (T1) and walking with the new orthosis (T2 and T3). Per condition, at least three valid trials will be used for analysis containing a clear stance phase on the force plate for both feet and full visibility of all markers during the gait cycle. Joint angles, net joint moments and joint powers around the hip, knee and ankle will be calculated per trial and averaged over three trials. Spatiotemporal gait parameters (such as step

length and step width) and relevant kinematic and kinetic variables (such as maximal ankle dorsiflexion angle, peak ankle power, knee angle and knee moment at midstance, hip flexion angle and maximal hip, knee and ankle angle during swing and progression of the centre of pressure) will be obtained from these averaged data and used for analysis.

Economic evaluation

The economic evaluation will be performed from a societal and a healthcare perspective. When the societal perspective is applied intervention costs (costs directly related to the delivery of the orthosis) healthcare costs (costs related to visits to general practitioners, medical specialists, and/or therapists, medication use and assistive devices) informal care costs, unpaid productivity costs, as well as costs related to productivity losses due to being absent from work (absenteeism) and productivity losses due to reduced productivity while being at work (presenteeism) will be included and assessed with a cost questionnaire. When the healthcare perspective is applied, only costs accruing to the formal Dutch healthcare system will be included. To collect data on resource use, participants are asked to fill in cost questionnaires at baseline (T1), directly after delivery of the orthosis and at 3 and 6 months post orthotic treatment (T2 and T3). All cost categories will be valued in accordance with the Dutch manual for costing studies in healthcare.⁴⁰

Outcome measures used for the economic evaluation will be quality-adjusted life years (QALYs), walking energy cost and GAS scores. QALYs will be based on the 5-Level version of EuroQol 5 Dimension (EQ-5D-5L), administered at each measurement point (T1, T2 and T3). The patients' EQ-5D-5L health states will be converted into utility scores using the Dutch tariff.⁴¹ Subsequently, QALYs will be estimated by multiplying the patients' utility scores by the time spent in a certain health state.

Statistical analysis

Walking energy cost and secondary outcomes at each measurement point (T1, T2 and T3) will be analysed with linear mixed models for repeated measurements to investigate the effectiveness of specialised orthotic care compared with usual orthotic care over time, adjusted for stratification and differences in baseline scores. Time and study group will be included as dependent variables. The differences in GAS scores between groups at 3 and 6 months follow-up will be tested with non-parametric Mann-Whitney U tests, as GAS scores are ordinal. All comparisons between groups are based on an intention-to-treat analysis.

For the economic evaluation, mean differences in total costs and effects between groups will be estimated using seemingly unrelated regression analyses. To account for the skewed nature of cost data, 95% CIs surrounding cost differences will be estimated using bias corrected and accelerated bootstrapping with 5000 replication. Subsequently, incremental cost-effectiveness ratios will

be calculated by dividing the mean differences in costs by the mean differences in effects. To illustrate the joint uncertainty surrounding costs and effects, cost-effectiveness planes and cost-effectiveness acceptability curves will be plotted. In a cost-effectiveness acceptability curve, the probability of specialised orthotic care being cost-effective compared with usual orthotic care is plotted for a range of willingness to pay values (ie, the amount of money decision-makers are willing to pay per unit of effect gained).

All statistical analyses will be performed using SPSS (V.25; IBM SPSS) and a statistical significance of $p < 0.05$ will be used in this study.

Patient and public involvement

Patients were actively involved in the preparation of this study through participating in meetings with the research group in the development stage of the study protocol and by providing feedback on the study procedures and the patient information documentation. During the conductance of the study, patients will be informed about the progress and involved in patient recruitment and the interpretation, reporting and dissemination of the results.

DISCUSSION

The aim of this study is to examine the effectiveness and cost-effectiveness of specialised orthotic care compared with usual orthotic care on functioning in adults with slowly progressive NMD. This study has several strengths.

First, a broad range of outcome measures on consecutive time points before and after orthotic treatment will be collected. For the examination of effectiveness, we will not only analyse objective outcome measures, such as walking energy cost and gait biomechanics, but also patient-reported outcome measures, like satisfaction with the provided orthosis. Besides, personal treatment goals will be set at the activity and participation level of the ICF and are therefore considered to be highly relevant to the patient. By assessing outcome measures from multiple perspectives, we will be able to fully capture the functional effects of specialised orthotic care and, at the same time, gain insight in the underlying biomechanical working mechanisms. Additionally, compared with previous research, evidence will be obtained in a large group of adults suffering from leg muscle weakness, caused by many different slowly progressive NMDs, which increases the generalisability of results.

Second, participants in the control group will be treated in a diverse sample of usual care centres in which leg orthoses are prescribed throughout the Netherlands. This allows for a broad comparison between specialised orthotic care and orthotic care as applied in current practice, which could be of importance for the improvement of overall quality and efficiency of orthotic care. On the other hand, treatment components of the usual care process are expected to differ among centres due to local policies and available facilities. This could complicate the

identification of underlying mechanisms of action that could explain differences in treatment outcomes between groups. To enable cautious exploration of potential mechanisms that might lead to beneficial treatment outcomes, which could be useful for future implications, the process of usual orthotic care will be extensively documented.

Finally, a major strength is the economic evaluation that will be performed alongside the study. Since expensive orthotic devices increasingly become available due to technological developments, it is important to not only assess whether orthotic devices are effective, but also whether their additional health effects are worth their additional costs. This study will be the first to provide insights into the cost-effectiveness of orthotic care in NMD in general and of specialised orthotic care compared with usual orthotic care in particular.

In conclusion, this study aims to examine the effectiveness and cost-effectiveness of specialised orthotic care compared with usual orthotic care in adults with NMD. Insights could lead to improvements in the quality of orthotic care resulting in improvements in overall functionality of adults with NMD in daily living. Consequently, insights could lead to a more efficient use of already scarce (healthcare) resources.

ETHICS AND DISSEMINATION

The study protocol was approved by the Medical Ethics committee of the Amsterdam UMC, location Academic Medical Center, ABR-number 67268. The study is registered at the Dutch Trial Register (NL7511) and will be performed in accordance with good clinical practice guidelines. An independent monitor of the Amsterdam UMC will monitor the study multiple times during the conduction of the study. Aspects that will be monitored will include inclusion rate, trial master file, informed consent process, inclusion and exclusion criteria, randomisation, trial procedures, source data verification, safety reporting and closing and reporting. The investigator will be encouraged to maintain the blinding as far as possible and code breaks should only occur in exceptional circumstances. Important protocol changes will be recorded (a new protocol version number will be assigned) and reported to the Medical Ethics Committee. When patients sign their informed consent, they will receive a participant ID, which will be coupled to all the data collected. Forms will be stored in a locked cabinet to assure anonymity. Only persons involved in the study have access to these forms. Insurance has been taken out for participation of patients in the study. After completion of the study, positive as well as negative or inconclusive results will be submitted to a peer-reviewed journal and presented at national and international scientific conferences. The study data sets and codes of the data analysis are available on request. Furthermore, results will be disseminated through other media aimed at a broader audience including patients. Participants will be informed about the results of the study by means of a newsletter.

Contributors M-AB, FSK and FN conceived the study. M-AB, FSK, FN, JMvD and EvD contributed to the study design and methods. M-AB, FSK, FN, JAMT, RL, VA and EvD participated in logistical planning of the study. EvD wrote the manuscript and is responsible for data acquisition and analysis. All authors conceived, provided feedback and approved the final version of the manuscript.

Funding This study was supported by ZonMw, The Netherlands Organisation for Health Research and Development, grant number: 853 001 103.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID ID

Elza van Duijnhoven <http://orcid.org/0000-0002-7876-046X>

REFERENCES

- Demir YP. Neuromuscular Diseases and Rehabilitation. In: Suzuki T, ed. *Neurological physical therapy. BoD – books on demand*, 2017.
- van der Krogt MM, Delp SL, Schwartz MH. How robust is human gait to muscle weakness? *Gait Posture* 2012;36:113–9.
- Brehm M-A, Nollet F, Harlaar J. Energy demands of walking in persons with postpoliomyelitis syndrome: relationship with muscle strength and reproducibility. *Arch Phys Med Rehabil* 2006;87:136–40.
- Menotti F, Felici F, Damiani A, et al. Charcot-Marie-Tooth 1A patients with low level of impairment have a higher energy cost of walking than healthy individuals. *Neuromuscul Disord* 2011;21:52–7.
- Abresch RT, Carter GT, Jensen MP, et al. Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease. *Am J Hosp Palliat Care* 2002;19:39–48.
- Bickerstaffe A, Beelen A, Nollet F. Circumstances and consequences of falls in polio survivors. *J Rehabil Med* 2010;42:908–15.
- Pieterse AJ, Lutikhoud TB, de Laat K, et al. Falls in patients with neuromuscular disorders. *J Neurol Sci* 2006;251:87–90.
- Ahlström G, Sjöden PO. Coping with illness-related problems and quality of life in adult individuals with muscular dystrophy. *J Psychosom Res* 1996;41:365–76.
- Johnson NE, Heatwole CR, Dilek N, et al. Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective. *Neuromuscul Disord* 2014;24:1018–23.
- Hsu JD, Michael JW, Fisk JR. *Atlas of orthoses and assistive devices*. 4 edn. Philadelphia: American Academy of Orthopedic Surgeons, 2008: 299–309.
- ISO. *ISO 8549-1 - Vocabulary - Part 1: general terms for external limb prostheses and external orthoses*. Genève: International Organization for Standardization, 1989.
- Hijmans JM, Geertzen JHB. Development of clinical guidelines for the prescription of orthoses in patients with neurological disorders in the Netherlands. *Prosthet Orthot Int* 2006;30:35–43.
- Heim S, Jacobs NA, Jensen JS. *ISPO consensus conference on poliomyelitis. consensus statement and Syndicate reports*. International Society of Prosthetics and Orthotics, 1997.
- van der Wilk D, Dijkstra PU, Postema K, et al. Effects of ankle foot orthoses on body functions and activities in people with floppy parietic ankle muscles: a systematic review. *Clin Biomech* 2015;30:1009–25.
- McDaid C, Fayter D, Booth A, et al. Systematic review of the evidence on orthotic devices for the management of knee instability related to neuromuscular and central nervous system disorders. *BMJ Open* 2017;7:e015927.

- 16 Brehm M-A, Beelen A, Doorenbosch CAM, *et al.* Effect of carbon-composite knee-ankle-foot orthoses on walking efficiency and gait in former polio patients. *J Rehabil Med* 2007;39:651–7.
- 17 Waterval NFJ, Brehm M-A, Harlaar J, *et al.* Description of orthotic properties and effect evaluation of ankle-foot orthoses in non-spastic calf muscle weakness. *J Rehabil Med* 2020;52.
- 18 Brehm M, Nollet F. *Beenorthesen bij neuromusculaire aandoeningen*. Amsterdam: Reed business education, 2014.
- 19 College van Zorgverzekeringen. *Procesbeschrijving hulpmiddelenzorg*. Den Haag: Nationaal ICT instituut in de Zorg, 2009.
- 20 WHO. *International classification of functioning, disability and health: ICF*. Genève: World Health Organization, 2001.
- 21 ISO. *ISO 9999 assistive products for persons with disability – classification and terminology, draft international standard*. Genève: International Organization for Standardization, 2010.
- 22 Hebert JS. Ambulatory KAFOs: a Physiatry perspective. *JPO Prosthet Orthot* 2006;18:P169–74.
- 23 Brehm M, Bus SA, Harlaar J, *et al.* A candidate core set of outcome measures based on the International classification of functioning, disability and health for clinical studies on lower limb orthoses. *Prosthet Orthot Int* 2011;35:269–77.
- 24 Waterval NFJ, Nollet F, Harlaar J, *et al.* Modifying ankle foot orthosis stiffness in patients with calf muscle weakness: gait responses on group and individual level. *J Neuroeng Rehabil* 2019;16:120.
- 25 Healy A, Farmer S, Eddison N, *et al.* A scoping literature review of studies assessing effectiveness and cost-effectiveness of prosthetic and orthotic interventions. *Disabil Rehabil Assist Technol* 2020;15:1–7.
- 26 Vinci P, Gargiulo P. Poor compliance with ankle-foot-orthoses in Charcot-Marie-Tooth disease. *Eur J Phys Rehabil Med* 2008;44:27–31.
- 27 Swinnen E, Kerckhofs E. Compliance of patients wearing an orthotic device or orthopedic shoes: a systematic review. *J Bodyw Mov Ther* 2015;19:759–70.
- 28 Chan A-W, Tetzlaff JM, Altman DG, *et al.* Spirit 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200–7.
- 29 Council MR. *Aids to examination of the peripheral nervous system. memorandum no 45*. London: Her Majesty's Stationary Office, 1976.
- 30 Garby L, Astrup A. The relationship between the respiratory quotient and the energy equivalent of oxygen during simultaneous glucose and lipid oxidation and lipogenesis. *Acta Physiol Scand* 1987;129:443–4.
- 31 Brehm M-A, Verduijn S, Bon J, *et al.* Comparison of two 6-minute walk tests to assess walking capacity in polio survivors. *J Rehabil Med* 2017;49:732–7.
- 32 Kempen JCE, Harlaar J, van der Kooi AJ, *et al.* Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy. *Neuromuscul Disord* 2014;24:216–21.
- 33 Steenbeek D, Ketelaar M, Galama K, *et al.* Goal attainment scaling in paediatric rehabilitation: a critical review of the literature. *Dev Med Child Neurol* 2007;49:550–6.
- 34 Steenbeek D, Meester-Delver A, Becher JG, *et al.* The effect of botulinum toxin type a treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling. *Clin Rehabil* 2005;19:274–82.
- 35 Dekkers K, de Viet E, Eilander H. *Goal attainment scaling (GAS) in de praktijk [Goal attainment scaling in clinical practice]*, 2011.
- 36 Gandek B, Ware JE, Aaronson NK, *et al.* Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA project. International quality of life assessment. *J Clin Epidemiol* 1998;51:1149–58.
- 37 Kempen GIJM, Yardley L, van Haastregt JCM, *et al.* The short FES-I: a shortened version of the falls efficacy scale-international to assess fear of falling. *Age Ageing* 2008;37:45–50.
- 38 Krupp LB, LaRocca NG, Muir-Nash J, *et al.* The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;46:1121–3.
- 39 Wessels RD, De Witte LP. Reliability and validity of the Dutch version of quest 2.0 with users of various types of assistive devices. *Disabil Rehabil* 2003;25:267–72.
- 40 Kanters TA, Bouwmans CAM, van der Linden N, *et al.* Update of the Dutch manual for costing studies in health care. *PLoS One* 2017;12:e0187477.
- 41 M Versteegh M, M Vermeulen K, M A A Evers S, *et al.* Dutch tariff for the five-level version of EQ-5D. *Value Health* 2016;19:343–52.

Supplementary file 1:

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	1-12
Protocol version	#3	Date and version identifier	1
Funding	#4	Sources and types of financial, material, and other support	12
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1, 12
Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	1
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	12
Roles and responsibilities: committees	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	12

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	5
Objectives	#7	Specific objectives or hypotheses	5
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	6
Methods: Participants, interventions, and outcomes			
Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6
Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	n/a
Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	n/a
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a

Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8
Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	6
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	6
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	6
Methods:			
Assignment of interventions (for controlled trials)			
Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	6-7
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	6-7
Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	6
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	7

Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	12
Methods: Data collection, management, and analysis			
Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	8-10
Data collection plan: retention	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	12
Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	10
Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	10
Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	10
Methods: Monitoring			
Data monitoring: formal committee	#21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be	12

		found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	
Data monitoring: interim analysis	#21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	12
Harms	#22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	6
Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	12
Ethics and dissemination			
Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	12
Protocol amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	12
Consent or assent	#26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6
Consent or assent: ancillary studies	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	12
Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	12
Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	12

Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	12
Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	12
Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	12
Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	12
Appendices			
Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	supplement 2
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist was completed on 22. April 2020 using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

Subject information**Supplementary file 2: consent form subject**

'Specialized orthotic care for people with leg muscle weakness'

- I have read the information letter. I was also able to ask questions. My questions have been answered sufficiently. I have had enough time to decide whether or not to participate.

- I understand that participation is voluntary. I also know that I may decide at any time to not participate or to stop participating in the study. Without having to provide any reason.

- I give consent for my general practitioner to be informed of my participation in this study.

- I give consent to information being requested from my specialist(s) treating me about my medical history.

- I give consent to collect and use my data for answering the research question in this study.

- I know that for study monitoring purposes some individuals could have access to all my data. Those people are listed in this information letter. I consent to that access by these persons.

- I give consent for my general practitioner and/or treating specialist to be informed of unexpected findings which are (may be) of interest for my health.

- I **give**
 do not give
consent for the further storage of my personal data for 15 years and retention for future research into the area of my disorder and the method of treatment.

- I **give**
 do not give
consent to being contacted again after this study for a follow-up study.

Subject information

- I want to participate in this study.

Name of subject:

Signature: Date : __ / __ / __

I certify that I have fully informed this subject about the said study.

If information becomes known during the study that could influence the consent of the subject, I will inform him/her of this on time.

Name of investigator :

Signature: Date: __ / __ / __

The subject will receive a complete information letter, together with a signed version of the informed consent form.